Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 1, 2007, Pages 211-218

  Krzyzanowska, Monika K ^a,b   Earle, Craig C ^a   Kuntz, Karen M ^c   Weeks, Jane C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness analysis; Fluorouracil; Gemcitabine; Pancreas cancer; Radiation

Indexed keywords

COMPUTER SIMULATION; COST EFFECTIVENESS; DECISION MAKING; PATIENT TREATMENT; TOXICITY; TUMORS;

ELDERLY PATIENTS; MARKOV MODEL; MULTIMODALITY THERAPY; PANCREAS CANCER;

RADIOTHERAPY;

FLUOROURACIL; GEMCITABINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG EFFICACY; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MEDICARE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; STATISTICAL MODEL; UNSPECIFIED SIDE EFFECT;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MARKOV CHAINS; MEDICARE; MODELS, ECONOMIC; PANCREATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 33845614902     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.1390     Document Type: Article

References (30)

1. Elixhauser A., and Halpern M.T. Economic evaluations of gastric and pancreatic cancer. Hepatogastroenterology 46 (1999) 1206-1213
2. Moertel C.G., Childs Jr. D.S., Reitemeier R.J., et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2 (1969) 865-867
3. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5- fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (1981) 1705-1710
4. Niederhuber J.E., Brennan M.F., and Menck H.R. The National Cancer Data Base report on pancreatic cancer. Cancer 76 (1995) 1671-1677
5. Janes Jr. R.H., Niederhuber J.E., Chmiel J.S., et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 223 (1996) 261-272
6. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189 (1999) 1-7
7. Krzyzanowska M.K., Weeks J.C., and Earle C.C. Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness. J Clin Oncol 21 (2003) 3409-3414
8. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15 (1997) 2403-2413
9. Storniolo A.M., Enas N.H., Brown C.A., et al. An investigational new drug treatment program for patients with gemcitabine: Results for over 3,000 patients with pancreatic carcinoma. Cancer 85 (1999) 1261-1268
10. Talamonti M.S., Catalano P.J., Vaughn D.J., et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 18 (2000) 3384-3389
11. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7 (2001) 2246-2253
12. Pipas J.M., Mitchell S.E., Barth Jr. R.J., et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50 (2001) 1317-1322
13. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17 (1999) 2208-2212
14. Blackstock A.W., Tempero M.A., Niedwiecki D., et al. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas [Abstract]. Proc Am Soc Clin Oncol 10 (2001) 627
15. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001) 4202-4208
16. Anderson R.N. A method for constructing complete annual U.S. life tables. Vital Health Stat 2 129 (2000) 1-28
17. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
18. Glimelius B., Hoffman K., Graf W., et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 6 (1995) 267-274
19. Brown M.L., Riley G.F., Potosky A.L., et al. Obtaining long-term disease specific costs of care: Application to Medicare enrollees diagnosed with colorectal cancer. Med Care 37 (1999) 1249-1259
20. Brown M.L., Riley G.F., Schussler N., et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40 (2002) 104-117
21. 2001 Red Book (2001), Medical Economics Company, Inc, Montvale, NJ
22. Earle C.C., Chapman R.H., Baker C.S., et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18 (2000) 3302-3317
23. Wilson L.S., and Lightwood J.M. Pancreatic cancer: Total costs and utilization of health services. J Surg Oncol 71 (1999) 171-181
24. Du W., Touchette D., Vaitkevicius V.K., et al. Cost analysis of pancreatic carcinoma treatment. Cancer 89 (2000) 1917-1924
25. Ragnarson-Tennvall G., and Wilking N. Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care. Pharmacoeconomics 15 (1999) 377-384
26. Cellini N., Costamagna G., Morganti A.G., et al. Concomitant radiochemotherapy in unresectable carcinoma of the exocrine pancreas: Cost-effectiveness analysis. Rays 24 (1999) 447-452
27. National Cancer Institute. Integrating economic analysis into cancer clinical trials: The National Cancer Institute-American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst Monogr (1998) 1-28
28. Glasziou P.P., Simes R.J., Hall J., et al. Design of a cost-effectiveness study within a randomized trial: The LIPID Trial for Secondary Prevention of IHD. Long-term intervention with Pravastatin in ischemic heart disease. Control Clin Trials 18 (1997) 464-476
29. Torgerson D.J., and Campbell M.K. Economics notes: Cost effectiveness calculations and sample size. BMJ 321 (2000) 697
30. Phase III randomized study of gemcitabine with or without radiotherapy in patients with locally advanced, unresectable pancreatic cancer. Available at: http://www.nci.nih.gov/ClinicalTrials/view_clinicaltrials.aspx?cdrid=278947&. Accessed Sept 3, 2004.